DENVER — Treatment with cannabidiol led to significant seizure reduction in those with focal-onset epilepsy and demonstrated a favorable safety profile, according to research presented at the ...

Learn how first-line antiepileptic drugs, personalized care, and lifestyle changes work together to manage generalized epilepsy effectively.

Long-term adjunctive perampanel treatment was efficacious and generally well tolerated among older patients with focal-onset seizures, according to findings presented at the annual meeting of the ...

Focal onset epilepsy seizures may impact your senses, causing unexplainable feelings, repetitive movements, and a loss of consciousness. Fortunately, there are many different treatments for focal ...

2. Focal onset seizures. These seizures start in a group of cells in one area of the brain and the effect of the seizure depends on where in the brain the abnormal firing occurs.

Focal onset seizures start on one side of the brain, while generalized onset seizures begin on both sides of the brain. Seizures can occur at varying levels of awareness and with varying symptoms.

Several seizure types previously listed only in the generalized category, such as tonic, atonic, clonic, myoclonic, infantile spasms (now epileptic spasms) now can also have focal onset. Other ...

People who get seizures that start on one side of the brain (called focal onset) are more likely to have clusters. But generalized onset seizures, which start on both sides of the brain, can also ...

Focal onset seizures. These seizures start in a group of cells in one area of the brain and the effect of the seizure depends on where in the brain the abnormal firing occurs.

“At present, there is insufficient evidence to inform clinical practice regarding clobazam monotherapy in focal or generalized seizures,” concluded the authors, adding “There is a definite ...

PORTO, Portugal and HATFIELD, England, March 28, 2017 /PRNewswire/ --FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN JOURNALISTSEfficacy and safety/t ...

The Phase 3 study was a multi-national, double-blind, randomized, placebo-controlled trial evaluating ganaxolone in 359 adult patients with drug-resistant focal onset seizures.